{"log_id": 7133520887346814248, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 0.021705, "average": 0.883151, "min": 0.675267}, "location": {"width": 31, "top": 109, "height": 78, "left": 1137}, "words": "明缝二"}, {"probability": {"variance": 2.1e-05, "average": 0.998388, "min": 0.973086}, "location": {"width": 773, "top": 230, "height": 29, "left": 261}, "words": "交叉耐药性:某些特定反转录酶抑制剂之间存在着交叉耐药性。由替诺福韦筛选"}, {"probability": {"variance": 0.003853, "average": 0.980509, "min": 0.6857}, "location": {"width": 810, "top": 275, "height": 27, "left": 218}, "words": "出的K65R突变在一些接受阿巴卡韦、去羟基苷、或扎西他滨治疗的HIV-1感染受试"}, {"probability": {"variance": 0.000605, "average": 0.992701, "min": 0.860567}, "location": {"width": 804, "top": 320, "height": 28, "left": 218}, "words": "者中也被筛选出来。含有这种突变的HIV分离病毒株对恩曲他滨和拉米夫定的敏感"}, {"probability": {"variance": 0.00012, "average": 0.995912, "min": 0.936148}, "location": {"width": 810, "top": 364, "height": 30, "left": 218}, "words": "性下降。因此,在携有K65R突变的患者中可能发生对这些药物的交叉耐药。从20"}, {"probability": {"variance": 0.002714, "average": 0.97917, "min": 0.710135}, "location": {"width": 772, "top": 406, "height": 28, "left": 219}, "words": "名平均出现3种与齐多夫定相关的反转录酶突变(M41L、D67N、K70R、L210W"}, {"probability": {"variance": 0.007248, "average": 0.976128, "min": 0.453166}, "location": {"width": 802, "top": 451, "height": 28, "left": 217}, "words": "T215Y/F、K219Q/EN)的受试者中分离出的HIV-1病毒株显示,对替诺福韦的敏感"}, {"probability": {"variance": 6.7e-05, "average": 0.995939, "min": 0.9747}, "location": {"width": 147, "top": 492, "height": 29, "left": 218}, "words": "性下降了3.1倍"}, {"probability": {"variance": 1e-05, "average": 0.997951, "min": 0.985}, "location": {"width": 764, "top": 538, "height": 30, "left": 260}, "words": "在对接受过治疗的受试者进行的研究902和907中(富马酸替诺福韦二吡呋酯+"}, {"probability": {"variance": 6e-06, "average": 0.998552, "min": 0.98821}, "location": {"width": 817, "top": 581, "height": 30, "left": 218}, "words": "标准背景治疗(SBT)与安慰剂+标准背景治疗),第96周期间接受富马酸替诺福韦"}, {"probability": {"variance": 0.000945, "average": 0.992587, "min": 0.80325}, "location": {"width": 796, "top": 624, "height": 29, "left": 220}, "words": "二吡呋酯治疗发生病毒学失败的受试者有14/304(5%),对替诺福韦的敏感性下降"}, {"probability": {"variance": 0.00279, "average": 0.98884, "min": 0.660811}, "location": {"width": 818, "top": 669, "height": 28, "left": 218}, "words": "超过1.4倍(中位值为2.7倍)。对在基线和失败时分离出的病毒株进行基因型分析的"}, {"probability": {"variance": 0.006917, "average": 0.980112, "min": 0.565691}, "location": {"width": 497, "top": 711, "height": 27, "left": 216}, "words": "结果表明,HIV-1反转录酶基因中出现了K65R突变"}, {"probability": {"variance": 0.000943, "average": 0.991553, "min": 0.80641}, "location": {"width": 751, "top": 754, "height": 32, "left": 259}, "words": "在参加研究902和907的接受过治疗的受试者中,在基线病毒基因型(N=222)"}, {"probability": {"variance": 6e-06, "average": 0.998335, "min": 0.990616}, "location": {"width": 546, "top": 798, "height": 29, "left": 217}, "words": "方面评价了患者对富马酸替诺福韦二吡呋酯的病毒学反应"}, {"probability": {"variance": 0.000375, "average": 0.992876, "min": 0.913342}, "location": {"width": 748, "top": 841, "height": 29, "left": 259}, "words": "在这些临床试验中,94%接受评价参与者的基线HIV-1分离病毒株表达了至少"}, {"probability": {"variance": 0.000195, "average": 0.995697, "min": 0.916831}, "location": {"width": 818, "top": 883, "height": 30, "left": 216}, "words": "种核苷反转录酶抑制剂(NRTI)突变。在基因亚型研究中,受试者病毒学反应与总体"}, {"probability": {"variance": 1e-06, "average": 0.998686, "min": 0.997608}, "location": {"width": 133, "top": 929, "height": 26, "left": 216}, "words": "试验结果相似"}, {"probability": {"variance": 1e-06, "average": 0.998998, "min": 0.994385}, "location": {"width": 770, "top": 971, "height": 31, "left": 260}, "words": "几项探索性分析评价了特定突变和突变模式对病毒学结果的影响。因为存在大量"}, {"probability": {"variance": 2e-06, "average": 0.998686, "min": 0.992439}, "location": {"width": 812, "top": 1016, "height": 28, "left": 216}, "words": "的比较方式,所以没有进行统计学检验。富马酸替诺福韦二吡呋酯对先前存在的与齐"}, {"probability": {"variance": 0.00823, "average": 0.958946, "min": 0.506662}, "location": {"width": 801, "top": 1058, "height": 30, "left": 216}, "words": "多夫定耐药相关的突变(M41L、D67N、K70R、L210W、T215Y/F、或K219Q/E/N)"}, {"probability": {"variance": 3.5e-05, "average": 0.996731, "min": 0.975705}, "location": {"width": 814, "top": 1100, "height": 29, "left": 216}, "words": "呈现不同程度交叉耐药性,其程度与特定突变的数目与种类相关。接受富马酸替诺福"}, {"probability": {"variance": 0.002037, "average": 0.980337, "min": 0.822184}, "location": {"width": 836, "top": 1142, "height": 33, "left": 216}, "words": "韦二吡呋酯治疗、出现3种或以上齐多夫定耐药相关突变(包含了M4L或L210W"}, {"probability": {"variance": 0.003274, "average": 0.983646, "min": 0.667592}, "location": {"width": 813, "top": 1184, "height": 29, "left": 215}, "words": "反转录酶突变)的HIV-1受试者对富马酸替诺福韦二吡呋酯治疗的应答降低;然而与"}, {"probability": {"variance": 0.004386, "average": 0.973538, "min": 0.636105}, "location": {"width": 804, "top": 1226, "height": 28, "left": 216}, "words": "安慰剂相比,这些受试者应答仍显示改善。D67N、K70R、T215Y/F、K219Q/EN突"}, {"probability": {"variance": 0.005115, "average": 0.982654, "min": 0.577025}, "location": {"width": 805, "top": 1268, "height": 30, "left": 215}, "words": "变的出现,似乎不影响对富马酸替诺福韦二吡呋酯治疗的应答。病毒出现L74V取代"}, {"probability": {"variance": 0.000235, "average": 0.994505, "min": 0.907653}, "location": {"width": 856, "top": 1310, "height": 34, "left": 215}, "words": "基因突变但无齐多夫定耐药相关取代基因突变的受试者(N=8)对富马酸替诺福韦二"}, {"probability": {"variance": 0.000734, "average": 0.989071, "min": 0.850725}, "location": {"width": 806, "top": 1353, "height": 27, "left": 215}, "words": "吡呋酯应答下降。病毒表达Y115F(N=3)、Q151M(N=2)取代基因突变或T69插"}, {"probability": {"variance": 6.8e-05, "average": 0.996099, "min": 0.955844}, "location": {"width": 651, "top": 1395, "height": 27, "left": 215}, "words": "入基因突变(N=4)的受试者相关数据有限,所有受试者应答均下降"}, {"probability": {"variance": 0, "average": 0.724101, "min": 0.724101}, "location": {"width": 41, "top": 1391, "height": 39, "left": 1067}, "words": "心"}, {"probability": {"variance": 0, "average": 0.957409, "min": 0.957409}, "location": {"width": 46, "top": 1436, "height": 44, "left": 1042}, "words": "它"}], "language": 3}